- Home
- BFST vs ETNB Comparison
BFST vs ETNB Comparison
Compare BFST & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- ETNB
- Stock Information
- Founded
- BFST 2006
- ETNB 2018
- Country
- BFST United States
- ETNB United States
- Employees
- BFST N/A
- ETNB N/A
- Industry
- BFST Major Banks
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- BFST Finance
- ETNB Health Care
- Exchange
- BFST Nasdaq
- ETNB Nasdaq
- Market Cap
- BFST 838.4M
- ETNB 1.0B
- IPO Year
- BFST 2018
- ETNB 2019
- Fundamental
- Price
- BFST $23.84
- ETNB $7.80
- Analyst Decision
- BFST Buy
- ETNB Strong Buy
- Analyst Count
- BFST 2
- ETNB 9
- Target Price
- BFST $30.00
- ETNB $27.25
- AVG Volume (30 Days)
- BFST 112.9K
- ETNB 1.5M
- Earning Date
- BFST 04-24-2025
- ETNB 05-01-2025
- Dividend Yield
- BFST 2.36%
- ETNB N/A
- EPS Growth
- BFST N/A
- ETNB N/A
- EPS
- BFST 2.43
- ETNB N/A
- Revenue
- BFST $276,739,000.00
- ETNB N/A
- Revenue This Year
- BFST $26.39
- ETNB N/A
- Revenue Next Year
- BFST $5.73
- ETNB N/A
- P/E Ratio
- BFST $9.67
- ETNB N/A
- Revenue Growth
- BFST 11.75
- ETNB N/A
- 52 Week Low
- BFST $18.97
- ETNB $4.16
- 52 Week High
- BFST $30.30
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- BFST 53.86
- ETNB 55.22
- Support Level
- BFST $23.20
- ETNB $7.40
- Resistance Level
- BFST $24.03
- ETNB $8.92
- Average True Range (ATR)
- BFST 0.64
- ETNB 0.54
- MACD
- BFST 0.17
- ETNB 0.14
- Stochastic Oscillator
- BFST 78.46
- ETNB 59.74
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a United States-based bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).